Sarwar Raiya, Pierce Nicholas, Koppe Sean
Department of Internal Medicine, University of Illinois at Urbana-Champaign, Champaign, IL, USA.
University of Medicine and Health Sciences, New York, NY, USA.
Diabetes Metab Syndr Obes. 2018 Sep 25;11:533-542. doi: 10.2147/DMSO.S146339. eCollection 2018.
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease due to an increase in the prevalence of obesity. The development of NASH leads to an increase in morbidity and mortality. While the first line of treatment is lifestyle modifications, including dietary changes and increased physical activity, there are no approved pharmacological treatment agents for NAFLD and NASH currently. Due to its complex pathophysiology, different pathways are under investigation for drug development with the focus on metabolic pathways, inflammation, and slowing or reversing fibrosis. There are several agents advancing in clinical trials, and promising results have been seen with drugs that affect hepatic steatosis, inflammation, and fibrosis. This review will provide an overview on NAFLD and some of the mechanisms of disease that are being targeted with pharmacologic agents.
由于肥胖患病率的增加，非酒精性脂肪性肝病（NAFLD）正迅速成为慢性肝病的最常见病因。非酒精性脂肪性肝炎（NASH）的发展导致发病率和死亡率上升。虽然一线治疗是生活方式的改变，包括饮食变化和增加体育活动，但目前尚无批准用于NAFLD和NASH的药物治疗药物。由于其复杂的病理生理学，目前正在研究不同的途径用于药物开发，重点是代谢途径、炎症以及减缓或逆转纤维化。有几种药物正在进行临床试验，并且已经在影响肝脂肪变性、炎症和纤维化的药物方面取得了有希望的结果。本综述将概述NAFLD以及正在用药物靶向治疗的一些疾病机制。
